| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Aflibercept a new target therapy in cancer treatment: a review
|
Ricci, Vincenzo
|
|
2015
|
96 |
3 |
p. 569-576
8 p.
|
artikel
|
| 2 |
An update on molecular biology and drug resistance mechanisms of multiple myeloma
|
Mutlu, Pelin
|
|
2015
|
96 |
3 |
p. 413-424
12 p.
|
artikel
|
| 3 |
Cytotoxic chemotherapy in the treatment of advanced renal cell carcinoma in the era of targeted therapy
|
Diamond, E.
|
|
2015
|
96 |
3 |
p. 518-526
9 p.
|
artikel
|
| 4 |
Editorial Board
|
|
|
2015
|
96 |
3 |
p. IFC-
1 p.
|
artikel
|
| 5 |
Health-related quality of life and symptom assessment in randomized controlled trials of patients with leukemia and myelodysplastic syndromes: What have we learned?
|
Cannella, Laura
|
|
2015
|
96 |
3 |
p. 542-554
13 p.
|
artikel
|
| 6 |
How medical choices influence quality of life of women carrying a BRCA mutation
|
Harmsen, Marline G.
|
|
2015
|
96 |
3 |
p. 555-568
14 p.
|
artikel
|
| 7 |
Immunotherapy for multiple myeloma: Current status and future directions
|
Ayed, Ayed O.
|
|
2015
|
96 |
3 |
p. 399-412
14 p.
|
artikel
|
| 8 |
Increased risk of bladder cancer in critical areas at high pressure of pollution of the Campania region in Italy: A systematic review
|
Di Lorenzo, Giuseppe
|
|
2015
|
96 |
3 |
p. 534-541
8 p.
|
artikel
|
| 9 |
Metastatic clear cell renal cell carcinoma: A review of current therapies and novel immunotherapies
|
Thomas, Jacob S.
|
|
2015
|
96 |
3 |
p. 527-533
7 p.
|
artikel
|
| 10 |
miRNA–mRNA crosstalk in esophageal cancer: From diagnosis to therapy
|
Sharma, Priyanka
|
|
2015
|
96 |
3 |
p. 449-462
14 p.
|
artikel
|
| 11 |
Potential role of Escherichia coli DNA mismatch repair proteins in colon cancer
|
Khan, Shahanavaj
|
|
2015
|
96 |
3 |
p. 475-482
8 p.
|
artikel
|
| 12 |
Proteomics in cancer research: Are we ready for clinical practice?
|
Maes, Evelyne
|
|
2015
|
96 |
3 |
p. 437-448
12 p.
|
artikel
|
| 13 |
Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials
|
Nagrial, Adnan M.
|
|
2015
|
96 |
3 |
p. 483-497
15 p.
|
artikel
|
| 14 |
Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer
|
Maines, Francesca
|
|
2015
|
96 |
3 |
p. 498-506
9 p.
|
artikel
|
| 15 |
Sympathetic blocks for visceral cancer pain management: A systematic review and EAPC recommendations
|
Mercadante, Sebastiano
|
|
2015
|
96 |
3 |
p. 577-583
7 p.
|
artikel
|
| 16 |
Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma
|
Carlino, Matteo S.
|
|
2015
|
96 |
3 |
p. 385-398
14 p.
|
artikel
|
| 17 |
Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance
|
Chang, Lei
|
|
2015
|
96 |
3 |
p. 507-517
11 p.
|
artikel
|
| 18 |
TET proteins in cancer: Current ‘state of the art’
|
Rawłuszko-Wieczorek, Agnieszka Anna
|
|
2015
|
96 |
3 |
p. 425-436
12 p.
|
artikel
|
| 19 |
Understanding next generation sequencing in oncology: A guide for oncologists
|
Moorcraft, Sing Yu
|
|
2015
|
96 |
3 |
p. 463-474
12 p.
|
artikel
|
Tijdschrift beschrijving